Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Operations: 2009-2024

Historic Cash from Operations for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $64.0 million.

  • Ani Pharmaceuticals' Cash from Operations rose 253.17% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.7 million, marking a year-over-year increase of 83.77%. This contributed to the annual value of $64.0 million for FY2024, which is 46.19% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Cash from Operations stood at $64.0 million for FY2024, which was down 46.19% from $119.0 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Cash from Operations high stood at $119.0 million for FY2023, and its period low was -$31.2 million during FY2022.
  • Over the past 3 years, Ani Pharmaceuticals' median Cash from Operations value was $64.0 million (recorded in 2024), while the average stood at $50.6 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Cash from Operations tumbled by 1,039.28% in 2022, and later skyrocketed by 481.24% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Cash from Operations (Yearly) stood at $15.3 million in 2020, then tumbled by 78.24% to $3.3 million in 2021, then slumped by 1,039.28% to -$31.2 million in 2022, then spiked by 481.24% to $119.0 million in 2023, then slumped by 46.19% to $64.0 million in 2024.